• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Invanz (ertapenem for injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Invanz (ertapenem for injection)

  • Profile

Profile

Contact Information

Contact: Merck
Website: https://www.merck.com/product/usa/pi_circulars/i/invanz/invanz_pi.pdf

Currently Enrolling Trials

    Show More

    General Information

    Invanz is a once-daily injectable penem antibiotic.

    Invanz is approved for use in adults for the treatment of moderate to severe infections caused by common gram-positive and gram-negative aerobic and anaerobic bacteria. Included, are community-acquired pneumonia, intra-abdominal, skin, urinary tract, kidney and post-surgical gynecological infections.

    Prior to administration, Invanz must be reconstituted and diluted.

    Invanz should be infused over 30 minutes in both the Treatment and Prophylactic regimens.

    Dosing considerations should be made in adults with advanced or end stage renal impairment and those on hemodialysis.

    Treatment regimen:

    • Adults and pediatric patients 13 years of age and older. The dosage should be 1 gram once a day intravenously or intramuscularly.
    • Patients 3 months to 12 years of age should be administered 15 mg/kg twice daily (not to exceed 1 g/day intravenously or intramuscularly.)
    • Intravenous infusion may be administered in adults and pediatrics for up to 14 days or intramuscular injection for up to 7 days.

    Prophylaxis regimen for adults:

    • 1 gram single dose given 1 hour prior to elective colorectal surgery.

    Mechanism of Action

    Invanz (ertapenem sodium) is a structurally unique 1-(beta) methyl-carbapenem related to a class of antibiotics known as beta-lactams, which includes penicillins and cephalosporins. Invanz works by blocking the formation of bacterial cell walls, thereby causing cell death.

    Side Effects

    Adverse events associated with the use of Invanz may include (but are not limited to) the following:

    • Diarrhea
    • Infused vein complications
    • Nausea
    • Headache
    • Vaginitis in females

    Clinical Trial Results

    The approval of Invanz is supported by studies conducted in more than 1,900 subjects, in five infectious disease categories. Treatment ranged from three to 14 days. Invanz exhibited an excellent safety profile and showed success rates equivalent to those of comparator antibiotics.

    Approval Date: 2001-11-01
    Company Name: Merck
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing